Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06056687
Other study ID # ALA in Ischemic Cardiomyopathy
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date February 1, 2024

Study information

Verified date February 2024
Source Damanhour University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effect of alpha-lipoic acid on inflammatory markers and cardiac fibrosis markers in diabetic patients with Ischemic Cardiomyopathy.


Description:

- A 3-month, prospective double blind interventional study, which will include 60 patients with type II Diabetes Mellitus with Ischemic Cardiomyopathy on optimal standard medical therapy, who will be consecutively randomized into two groups, group on ALA 600 mg once daily and the second group on placebo once daily. - Approval will be obtained from Research and Ethics Committee of Faculty of Pharmacy, Damanhour University. A written informed consent will be obtained from patients before begining of the study. - All patients will undergo complete physical examination at baseline and after 3 months of treatment. - Patients will be assessed using Echocardiography before and after the study focusing on: Left atrial diameter (LAD), basic left ventricular dimensions (EDD and ESD) and both systolic and diastolic function. -Measurements of inflammatory markers such as [C-reactive protein (CRP), Tumor necrosis factor alpha (TNFα)] and fibrosis markers such as [Transforming growth factor beta (TGFβ), Matrix metalloproteinase 2 (MMP-2)] at the beginning of the study and after 3 months of the study. Study Outcomes: all patients will be followed up for 3 months for: - 1ry outcomes: Change in inflammatory and fibrosis markers levels. LV Echocardiography improvements of any of basic Echo parameters. - 2ry outcomes: Major Adverse Cardiovascular Events (MACE) such as MI, stroke or death. any side effects of the drug. Results The results of the study will be tabulated and statistical tests appropriate to the study will be conducted to evaluate significance of results. conclusion Conclusion, and recommendations will be given.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 1, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion criteria: - Type 2 diabetes with a history of CAD. - LV ejection fraction (LVEF) =40%. - Ischemic heart failure patients with NYHA grade II-IV. Exclusion criteria: - Type 1 diabetes. - Severe CKD with GFR = 15 ml/min/1.73m^2. - Severe liver disease. - Thyroid disorders. - Acute febrile illness. - Autoimmune disorders or connective tissue disorders.

Study Design


Intervention

Drug:
Alpha Lipoic Acid 600 MG Oral Tablet
Alpha Lipoic Acid 600 MG Oral Tablet once daily
Other:
Placebo Tablet
Placebo Tablet once daily

Locations

Country Name City State
Egypt Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes. Damanhur Elbehairah

Sponsors (1)

Lead Sponsor Collaborator
Damanhour University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary C-reactive protein (CRP) Serum Biomarker (mg/ml) 3 month
Primary Tumor necrosis factor alpha (TNFa)] Serum Biomarker (pg/ml) 3 Months
Primary Transforming growth factor beta (TGFß) fibrosis markers (ng/ml) 3 Months
Primary Matrix metalloproteinase 2 (MMP-2) fibrosis markers (ng/ml) 3 Months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A